Trial

Researchers testing C. diff vaccine in widespread trial

Researchers testing C. diff vaccine in widespread trial

By

An international trial is examining the efficacy of a vaccine for C. difficile, the gut-destroying bacterium that is particularly dangerous to seniors.

Biogen shortens name, raises hopes

Biogen Idec, which was heralded last week for results of an Alzheimer's drug trial, has shortened its name and chosen a new logo. It will now be known as Biogen (Nasdag: BIIB).

C. diff spotlight: Vaccine trial and caregiver checklist

C. diff spotlight: Vaccine trial and caregiver checklist

By

Back in June, I declared medication to be the long-term care topic of the summer. But this week, a different topic has stolen the spotlight: Clostridium difficile.